Lisata Therapeutics, Inc.
LSTA
$1.09
-$0.04-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -90.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -90.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -90.00% | -- | -- |
| SG&A Expenses | 26.93% | 15.19% | -31.81% | -12.13% | -8.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.16% | -15.48% | -46.56% | -17.28% | -10.59% |
| Operating Income | 18.00% | 15.48% | 37.79% | 17.28% | 11.86% |
| Income Before Tax | 37.13% | 14.25% | 35.92% | 13.81% | 7.63% |
| Income Tax Expenses | -- | 59.77% | -- | -- | -- |
| Earnings from Continuing Operations | 37.13% | 4.97% | 35.92% | 13.81% | 7.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.13% | 4.97% | 35.92% | 13.81% | 7.63% |
| EBIT | 18.00% | 15.48% | 37.79% | 17.28% | 11.86% |
| EBITDA | 17.31% | 14.89% | 37.57% | 17.45% | 11.94% |
| EPS Basic | 40.58% | 9.25% | 38.88% | 17.92% | 10.82% |
| Normalized Basic EPS | 40.60% | 18.74% | 38.87% | 17.93% | 10.83% |
| EPS Diluted | 40.58% | 9.25% | 38.88% | 17.92% | 10.82% |
| Normalized Diluted EPS | 40.60% | 18.74% | 38.87% | 17.93% | 10.83% |
| Average Basic Shares Outstanding | 5.82% | 4.70% | 4.84% | 5.01% | 3.57% |
| Average Diluted Shares Outstanding | 5.82% | 4.70% | 4.84% | 5.01% | 3.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |